MRUS
Merus N.V

1,082
Loading...
Loading...
News
all
press releases
Merus N.V. (MRUS) Reports Q2 Loss, Misses Revenue Estimates
Merus (MRUS) delivered earnings and revenue surprises of -90.60% and -15.41%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
More News
News Placeholder
BioMarin Pharmaceutical (BMRN) Q2 Earnings and Revenues Surpass Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of +39.81% and +7.72%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·2mo ago
News Placeholder
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Merus jumps 30% in three months after its cancer combo therapy showed significant efficacy in a phase II head and neck squamous cell carcinoma study.
Zacks·2mo ago
News Placeholder
Merus Stock Soars On Positive Phase 2 Drug Trial Data, Price Target Hikes: Retail’s Thrilled
BofA’s new price target of $92 implies a 121% upside to Merus’s closing share price of $41.6 on Thursday.
Stocktwits·4mo ago
News Placeholder
Earnings Preview: Merus N.V. (MRUS) Q1 Earnings Expected to Decline
chainwire·5mo ago
News Placeholder
Sarepta, other biotech stocks tumble as FDA appoints new CBER director
Investing.com -- Shares of several biotech companies experienced significant declines in Tuesday’s trading session following the announcement of Dr. Vinay Prasad as the new director of the Center for Biologics Evaluation and Research (CBER) at the FDA. Modernal stock fell 12%, Sarepta Therapeutics (NASDAQ:SRPT) shares dropped 25%, Capricor Therapeutics (NASDAQ:CAPR) plummeted 24%, and Arcellx declined by 16%.
investing.com·5mo ago
News Placeholder
Lightning Round: Take some Sterling Infrastructure off the table, let the rest run, says Jim Cramer
'Mad Money' host Jim Cramer weighs in on stock including: Allison Transmission, Nano Nuclear Energy, Sterling Infrastructure, and Merus...
CNBC Television-YouTube·10mo ago
News Placeholder
Cramer's Lightning Round: Merus is 'very speculative'
"Mad Money" host Jim Cramer rings the lightning round bell, which means he's giving his answers to callers' stock questions at rapid speed...
CNBC: Mad Money with Jim Cramer·10mo ago
News Placeholder
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates
Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates Biotech Innovations: Revolutionary Treatments Aim to Boost Pancreatic Cancer Survival Rates PR Newswire...
PR Newswire·1y ago
News Placeholder
Why Is Cancer-Focused Merus Stock Trading Over 30% On Friday?
Merus announces interim clinical data on petosemtamab and Keytruda (pembrolizumab) for first-line recurrent/metastatic head and neck squamous cell carcinoma. Early results show promising efficacy...
Benzinga·1y ago

Latest MRUS News

View

Advertisement. Remove ads.

Advertisement. Remove ads.